Rimegepant
| 證據等級: L5 | 預測適應症: 6 個 |
目錄
Rimegepant: From Migraine to Migraine with Brainstem Aura
One-Sentence Summary
Rimegepant is a CGRP receptor antagonist approved by the FDA for acute and preventive treatment of migraine. The TxGNN model predicts it may also be effective for Migraine with Brainstem Aura, with no dedicated clinical trials but 14 supporting publications on rimegepant in general migraine populations.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available in local license data (drug not currently marketed); per FDA approval documented in literature: acute treatment of migraine with or without aura, and preventive treatment of episodic migraine |
| Predicted New Indication | Migraine with Brainstem Aura |
| TxGNN Prediction Score | 99.94% |
| Evidence Level | L4 |
| US Market Status | Not Marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in structured form. Based on the literature evidence collected, rimegepant is a small-molecule calcitonin gene-related peptide (CGRP) receptor antagonist that blocks CGRP signalling in the trigeminovascular system. It was first approved by the FDA in 2020 (Nurtec® ODT) for acute treatment of migraine with or without aura, and later for preventive treatment of episodic migraine.
The predicted new indication, migraine with brainstem aura, is a specific migraine subtype. Unlike triptans, gepants such as rimegepant do not cause vasoconstriction, which theoretically makes them more suitable for this subtype — brainstem aura and hemiplegic migraine have traditionally been considered a relative or absolute contraindication for triptans due to their vasoconstrictive action. This pharmacological distinction provides a plausible mechanistic rationale for the TxGNN prediction.
However, all 14 literature items identified relate to general migraine populations (efficacy, safety, pharmacokinetics, long-term open-label studies); none specifically enrolled or studied patients with migraine with brainstem aura, a subgroup that is routinely excluded from standard migraine RCTs. The current evidence is therefore an indirect extrapolation from mechanism plus general-population efficacy/safety data, not direct evidence for this specific subtype.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 35790906 | 2022 | Network meta-analysis | J Headache Pain | Indirect comparison of relative efficacy: rimegepant vs. lasmiditan and ubrogepant for acute migraine treatment |
| 41366286 | 2025 | Phase 4 open-label safety | J Headache Pain | 24-week open-label study confirms long-term safety/tolerability of once-daily 75 mg rimegepant for episodic migraine prevention |
| 41066271 | 2025 | Phase 3 open-label long-term safety | Cephalalgia | Long-term safety and effectiveness of rimegepant ODT 75 mg for acute migraine treatment in Chinese adults |
| 41652664 | 2026 | Retrospective cohort | Headache | Off-label use of rimegepant in adolescents shows favorable tolerability and effectiveness for acute migraine |
| 41133671 | 2026 | Phase 1 PK/Safety | Headache | Single-dose PK, safety, and tolerability of weight-adjusted rimegepant ODT in children aged 6–12 with migraine history |
| 36808268 | 2023 | Phase 1 RCT (PK/Safety) | Clin Pharmacol Drug Dev | Randomized placebo-controlled trial confirms PK and safety of single/multiple 75 mg rimegepant ODT dosing in healthy Chinese adults |
| 36739335 | 2023 | Review | CNS Drugs | Comprehensive review of rimegepant’s efficacy in acute and preventive migraine treatment; superior to placebo in pivotal Phase 3 trials |
| 32270407 | 2020 | Review (drug approval summary) | Drugs | First-approval summary of rimegepant ODT for acute migraine; conventional tablet under investigation for prevention and trigeminal neuralgia |
| 38307667 | 2024 | Review | Handb Clin Neurol | Review of second-generation CGRP receptor antagonists (gepants) including rimegepant, mechanism and clinical development |
| 33550872 | 2021 | Review | Pain Manag | Overview of rimegepant among new acute migraine treatment options (lasmiditan, ubrogepant, rimegepant) |
US Market Information
Rimegepant is not currently marketed in this jurisdiction — no license/NDA records are available.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The CGRP-antagonist, non-vasoconstrictive mechanism offers a plausible rationale for use in migraine with brainstem aura, and rimegepant has substantial general-population migraine evidence (including Phase 3/4 studies). However, no clinical trial or publication directly studies this specific subtype, and a Blocking data gap on official safety warnings/contraindications (DG001) prevents entry into the S1 safety evaluation stage.
To proceed, the following is needed:
- Official label warnings, contraindications, and DDI data (TFDA or equivalent regulatory source)
- Formal mechanism of action (MOA) documentation from DrugBank
- Subtype-specific evidence (case series, registry data, or targeted trials) in migraine with brainstem aura or hemiplegic migraine populations
- Confirmation of local regulatory pathway, given the drug is not currently marketed in this jurisdiction
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.